Myelodysplastic Syndromes

Myelodysplastic Syndrome

Types

Book Appointment

Myelodysplastic Syndromes (MDS) are a group of rare but serious blood and bone marrow disorders. In MDS, the bone marrow—the spongy tissue inside bones that produces blood cells—fails to make enough healthy blood cells. Instead, it produces immature or abnormal cells that do not function properly. Over time, this leads to anemia, frequent infections, excessive bleeding, and, in some cases, progression to acute myeloid leukemia (AML). Once considered difficult to manage, MDS is now better understood thanks to advances in genetics and treatment research. Although it most commonly affects older adults, anyone can be diagnosed. Early recognition, precise diagnosis, and tailored treatment are essential to improving outcomes.

What Is Myelodysplastic Syndrome (MDS)?

MDS is classified as a type of bone marrow failure disorder. In healthy individuals, bone marrow produces:

Red blood cells (RBCs) to carry oxygen.
White blood cells (WBCs) to fight infection.
Platelets to control bleeding.

In MDS, abnormal stem cells in the bone marrow create defective blood cells. These immature cells die earlier than normal, leaving fewer healthy cells in circulation. This condition is sometimes called “pre-leukemia” because of its potential to progress to acute myeloid leukemia.

Types of MDS

The World Health Organization (WHO) classifies MDS into several subtypes based on blood cell appearance and genetic changes:

MDS with single lineage dysplasia (MDS-SLD)
- Only one type of blood cell is affected (RBCs, WBCs, or platelets).
MDS with multilineage dysplasia (MDS-MLD)
- Two or more blood cell types are abnormal.
MDS with ring sideroblasts (MDS-RS)
- Bone marrow produces red blood cells containing iron deposits in a ring shape.
MDS with excess blasts (MDS-EB)
- Higher numbers of immature blood cells (blasts) are present.
- Higher risk of progression to AML.
MDS with isolated del(5q) abnormality
- Characterized by a specific chromosomal deletion on chromosome 5.
- Often associated with better prognosis when treated properly.
Unclassifiable MDS (MDS-U)

Does not fit neatly into other categories but still shows bone marrow abnormalities.

Causes and Risk Factors

MDS arises when bone marrow stem cells acquire genetic mutations. While the exact cause is not always clear, risk factors include:

Age – Most cases occur in people over 60.
Previous cancer treatment – Chemotherapy and radiation increase MDS risk.
Exposure to chemicals – Benzene, pesticides, and industrial solvents are linked to higher rates.
Smoking – Long-term smoking is associated with DNA mutations.
Genetic predisposition – Rare inherited syndromes such as Fanconi anemia.
Other blood disorders – Long-standing bone marrow problems can evolve into MDS.

Symptoms of MDS

Many patients are asymptomatic in early stages, and the condition is often discovered during routine blood tests. Common symptoms include:

Fatigue and weakness – Caused by anemia.
Shortness of breath – Especially during physical activity.
Frequent infections – Due to low white blood cell counts.
Easy bruising and bleeding – From reduced platelets.
Pale or yellowish skin – Linked to low red blood cell levels.
Unexplained weight loss or fever – Seen in progressive disease.

Because symptoms overlap with other illnesses, early medical evaluation is critical.

Diagnosis of Myelodysplastic Syndromes

Doctors use a combination of tests to confirm MDS:

Complete Blood Count (CBC) – Detects abnormal blood cell counts.
Peripheral blood smear – Examines cell size, shape, and maturity.
Bone marrow biopsy and aspiration – The most definitive test.
Cytogenetic testing – Identifies chromosomal abnormalities.
Molecular genetic testing – Looks for specific gene mutations (e.g., TP53, SF3B1, RUNX1).

Diagnosis also includes risk stratification, using scoring systems like:

International Prognostic Scoring System (IPSS)
Revised IPSS (IPSS-R)

These tools assess survival chances and progression risk to AML.

Treatment Options for MDS

The choice of treatment depends on age, health, risk category, and subtype. Treatments are often divided into supportive care, disease-modifying therapies, and curative options.

1. Supportive Care

Blood transfusions – For anemia and low platelets.
Growth factors – Erythropoietin (EPO) to stimulate RBC production, G-CSF for WBCs.
Antibiotics – To fight recurrent infections.
Iron chelation therapy – Reduces excess iron from repeated transfusions.

2. Drug Therapies

Hypomethylating agents (HMAs) – Azacitidine and decitabine slow disease progression and improve survival.
Immunomodulatory drugs – Lenalidomide is effective for patients with 5q deletion.
Targeted therapies – New drugs target specific mutations (e.g., IDH inhibitors).

3. Stem Cell (Bone Marrow) Transplant

The only curative treatment for MDS.
Replaces diseased marrow with healthy donor stem cells.
Best suited for younger patients with high-risk disease.

4. Clinical Trials

Research is ongoing in CAR-T cell therapy, gene editing, and next-generation targeted drugs.
Clinical trials provide access to emerging treatments.

Living with MDS

Managing MDS requires not just medical treatment but also lifestyle adjustments:

Nutrition – A diet rich in protein, iron, and vitamins supports blood health.
Exercise – Light to moderate activity improves stamina and reduces fatigue.
Infection prevention – Hand hygiene, vaccinations, and avoiding crowded places during low immunity.
Mental health – Counseling and support groups help manage stress and uncertainty.
Regular monitoring – Frequent blood tests are essential to track disease progression.

Prognosis and Outlook

MDS prognosis varies widely:

Low-risk MDS – Patients may live many years with supportive care.
High-risk MDS – Greater likelihood of progression to AML within months to years.
Stem cell transplant recipients – Can achieve long-term remission but face risks of complications.

Survival depends on:

Percentage of blasts in bone marrow.
Chromosomal abnormalities.
Number of blood cell lines affected.

With ongoing research, survival rates are improving, and patients now have more options than ever before.

Conclusion

Myelodysplastic Syndromes are complex blood disorders that demand accurate diagnosis, personalized treatment, and long-term care. While there is currently no universal cure, therapies such as stem cell transplantation and hypomethylating agents are offering patients better survival and quality of life. Early detection and active disease monitoring are essential in improving outcomes. Raising awareness of MDS ensures that more people recognize the symptoms early and seek timely medical attention. With rapid advances in research, the future holds greater hope for patients and families affected by MDS.

Book Appointment

MDS is classified as a type of bone marrow failure disorder. In healthy individuals, bone marrow produces:

Red blood cells (RBCs) to carry oxygen.
White blood cells (WBCs) to fight infection.
Platelets to control bleeding.

The World Health Organization (WHO) classifies MDS into several subtypes based on blood cell appearance and genetic changes:

MDS with single lineage dysplasia (MDS-SLD)
- Only one type of blood cell is affected (RBCs, WBCs, or platelets).
MDS with multilineage dysplasia (MDS-MLD)
- Two or more blood cell types are abnormal.
MDS with ring sideroblasts (MDS-RS)
- Bone marrow produces red blood cells containing iron deposits in a ring shape.
MDS with excess blasts (MDS-EB)
- Higher numbers of immature blood cells (blasts) are present.
- Higher risk of progression to AML.
MDS with isolated del(5q) abnormality
- Characterized by a specific chromosomal deletion on chromosome 5.
- Often associated with better prognosis when treated properly.
Unclassifiable MDS (MDS-U)

Does not fit neatly into other categories but still shows bone marrow abnormalities.

MDS arises when bone marrow stem cells acquire genetic mutations. While the exact cause is not always clear, risk factors include:

Age – Most cases occur in people over 60.
Previous cancer treatment – Chemotherapy and radiation increase MDS risk.
Exposure to chemicals – Benzene, pesticides, and industrial solvents are linked to higher rates.
Smoking – Long-term smoking is associated with DNA mutations.
Genetic predisposition – Rare inherited syndromes such as Fanconi anemia.
Other blood disorders – Long-standing bone marrow problems can evolve into MDS.

Many patients are asymptomatic in early stages, and the condition is often discovered during routine blood tests. Common symptoms include:

Fatigue and weakness – Caused by anemia.
Shortness of breath – Especially during physical activity.
Frequent infections – Due to low white blood cell counts.
Easy bruising and bleeding – From reduced platelets.
Pale or yellowish skin – Linked to low red blood cell levels.
Unexplained weight loss or fever – Seen in progressive disease.

Because symptoms overlap with other illnesses, early medical evaluation is critical.

Doctors use a combination of tests to confirm MDS:

Complete Blood Count (CBC) – Detects abnormal blood cell counts.
Peripheral blood smear – Examines cell size, shape, and maturity.
Bone marrow biopsy and aspiration – The most definitive test.
Cytogenetic testing – Identifies chromosomal abnormalities.
Molecular genetic testing – Looks for specific gene mutations (e.g., TP53, SF3B1, RUNX1).

Diagnosis also includes risk stratification, using scoring systems like:

International Prognostic Scoring System (IPSS)
Revised IPSS (IPSS-R)

These tools assess survival chances and progression risk to AML.

The choice of treatment depends on age, health, risk category, and subtype. Treatments are often divided into supportive care, disease-modifying therapies, and curative options.

1. Supportive Care

Blood transfusions – For anemia and low platelets.
Growth factors – Erythropoietin (EPO) to stimulate RBC production, G-CSF for WBCs.
Antibiotics – To fight recurrent infections.
Iron chelation therapy – Reduces excess iron from repeated transfusions.

2. Drug Therapies

Hypomethylating agents (HMAs) – Azacitidine and decitabine slow disease progression and improve survival.
Immunomodulatory drugs – Lenalidomide is effective for patients with 5q deletion.
Targeted therapies – New drugs target specific mutations (e.g., IDH inhibitors).

3. Stem Cell (Bone Marrow) Transplant

The only curative treatment for MDS.
Replaces diseased marrow with healthy donor stem cells.
Best suited for younger patients with high-risk disease.

4. Clinical Trials

Research is ongoing in CAR-T cell therapy, gene editing, and next-generation targeted drugs.
Clinical trials provide access to emerging treatments.

Managing MDS requires not just medical treatment but also lifestyle adjustments:

Nutrition – A diet rich in protein, iron, and vitamins supports blood health.
Exercise – Light to moderate activity improves stamina and reduces fatigue.
Infection prevention – Hand hygiene, vaccinations, and avoiding crowded places during low immunity.
Mental health – Counseling and support groups help manage stress and uncertainty.
Regular monitoring – Frequent blood tests are essential to track disease progression.

MDS prognosis varies widely:

Low-risk MDS – Patients may live many years with supportive care.
High-risk MDS – Greater likelihood of progression to AML within months to years.
Stem cell transplant recipients – Can achieve long-term remission but face risks of complications.

Survival depends on:

Percentage of blasts in bone marrow.
Chromosomal abnormalities.
Number of blood cell lines affected.

With ongoing research, survival rates are improving, and patients now have more options than ever before.

Frequently Asked Questions

Myelodysplastic syndrome (MDS) is a group of disorders where the bone marrow does not produce enough healthy blood cells. Instead, it makes immature or abnormal cells that cannot function properly. This leads to anemia, infections, or bleeding issues. MDS is sometimes called a “bone marrow failure disorder” and may progress into acute myeloid leukemia in severe cases.

The four main types of myelodysplastic syndrome include refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), refractory anemia with excess blasts (RAEB), and chronic myelomonocytic leukemia (CMML). Each type is classified based on abnormal cell development in bone marrow and blood, severity of symptoms, and risk of progression to acute leukemia. Proper diagnosis guides treatment options.

Life expectancy in myelodysplastic syndrome varies depending on the type, age, and treatment response. Some low-risk cases progress slowly, allowing patients to live for years with proper management, while high-risk cases may advance quickly to leukemia. On average, survival ranges from less than a year to over a decade. Advances in treatments continue to improve outcomes.